WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 522376
CAS#: 1254036-66-2 (free base)
Description: GSK2292767 is a potent and selective PI3Kδ inhibitor. GSK2292767 is is currently in clinical trials for the treatment of respiratory diseases such as asthma and COPD. GSK2292767 is highly selective for PI3Kδ over the closely related isoforms and are active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation. PI3Kδ is highly enriched in leukocytes, making it an attractive target for the treatment of inflammatory conditions, such as asthma,6 chronic obstructive pulmonary disease (COPD), and autoimmune diseases.
MedKoo Cat#: 522376
Name: GSK2292767
CAS#: 1254036-66-2 (free base)
Chemical Formula: C24H28N6O5S
Exact Mass: 512.18419
Molecular Weight: 512.58
Elemental Analysis: C, 56.24; H, 5.51; N, 16.40; O, 15.61; S, 6.25
GSK2292767, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: GSK2292767; GSK-2292767; GSK 2292767.
IUPAC/Chemical Name: N-(5-(4-(5-(((2R,6S)-2,6-dimethylmorpholino)methyl)oxazol-2-yl)-1H-indazol-6-yl)-2-methoxypyridin-3-yl)methanesulfonamide
InChi Key: NLUPPCTVKHDVIQ-GASCZTMLSA-N
InChi Code: InChI=1S/C24H28N6O5S/c1-14-11-30(12-15(2)34-14)13-18-9-26-23(35-18)19-5-16(6-21-20(19)10-27-28-21)17-7-22(29-36(4,31)32)24(33-3)25-8-17/h5-10,14-15,29H,11-13H2,1-4H3,(H,27,28)/t14-,15+
SMILES Code: CS(=O)(NC1=CC(C2=CC3=C(C(C4=NC=C(CN5C[C@@H](C)O[C@@H](C)C5)O4)=C2)C=NN3)=CN=C1OC)=O
The following data is based on the product molecular weight 512.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Down KD, Amour A, Baldwin IR, Cooper AW, Deakin AM, Felton LM, Guntrip SB,
Hardy C, Harrison ZA, Jones KL, Jones P, Keeling SE, Le J, Livia S, Lucas F,
Lunniss CJ, Parr NJ, Robinson E, Rowland P, Smith S, Thomas DA, Vitulli G, Washio
Y, Hamblin N. Optimization of Novel Indazoles as Highly Potent and Selective
Inhibitors of Phosphoinostide-3-Kinase Delta for the Treatment of Respiratory
Disease. J Med Chem. 2015 Aug 24. [Epub ahead of print] PubMed PMID: 26301626.
GSK2292767 is an analogue of GSK2269557